You just read:

Santaris Pharma A/S Advances New Cholesterol-Lowering Drug, SPC5001 Inhibiting Exciting New Target PCSK9, Into Phase 1 Clinical Trials for the Treatment of High Cholesterol

News provided by

Santaris Pharma A/S

04 May, 2011, 12:15 BST